August 6, 2018 by Chain Drug Review
LLC, Lucemyra, Mark McKenna, Opioid Withdrawal Syndrome, P. Breckinridge Jones, Salix Pharmaceuticals, US WorldMeds
Pharmacy, Supplier News

LOUISVILLE, K.Y. and BIDGEWATER, N.J. – US WorldMeds, LLC, and Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies Inc., today announced the U.S. launch and availability of Lucemyra (lofexidine) 0.18 mg tablets, the first and only non-opioid medication indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. The Centers
August 6, 2018 by Chain Drug Review
and Bradford Rx Solutions, Drug Supply Chain Security Act, HDA Research Foundation, Kindler & Crimmins Associates, LLC, The Role of Reverse Distribution
Business, Leading Headlines, Pharmacy, Supplier News

ARLINGTON, Va.— A new report published by the HDA Research Foundation entitled The Role of Reverse Distribution provides insights into the reverse distribution of pharmaceutical products. The Foundation estimates that this channel accounts for 3.5 to 4% of all pharmaceutical sales — more than 120 million product units — and exceeds $13 billion in product value. Reverse distribution
May 30, 2018 by Chain Drug Review
Activ Nutritional, Adare Pharmaceuticals, Craig Sheehan, Lactobacillus LB Fermentate, LLC, Rite Aid, Viactiv Digestive Health
Supplier News

LAWRENCEVILLE, N.J. — Adare Pharmaceuticals’ consumer products subsidiary (Activ Nutritional, LLC), has launched new Viactiv Digestive Health Soft Chews, expanding the Viactiv supplement brand into the growing digestive health category. New Viactiv Digestive Health are said to be the only 2-in-1 supplement to combine a probiotic-derived, clinically-studied strain that helps feed good bacteria and fight bad bacteria to
May 2, 2018 by Chain Drug Review
Doxazosin Tablets, LLC, Upsher-Smith Laboratories
Pharmacy, Supplier News

MAPLE GROVE, Minn. — Upsher-Smith Laboratories, LLC (Upsher-Smith) announced the launch of Doxazosin tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg. The product was approved by the U.S. Food and Drug Administration (FDA) on April 17, 2018. Upsher-Smith’s Doxazosin tablets are an AB-rated generic version of the branded product, Cardura (doxazosin mesylate